Interleukin-18, Interleukin-20, and Matrix Metalloproteinases (MMP-1, MMP-3) As Markers of Psoriatic Arthritis Disease Severity and Their Correlations with Biomarkers of Inflammation and Turnover of Joint Cartilage

Overview

Journal Postepy Dermatol Alergol

Publisher Termedia

Specialty Allergy & Immunology

Date 2021 Feb 19

PMID 33603622

Citations 8

Authors

Michal Waszczykowski

Igor Bednarski

Joanna Narbutt

Elzbieta Waszczykowska

Aleksandra Lesiak

Jaroslaw Fabis

Affiliations

Soon will be listed here.

Abstract

Introduction: Psoriatic arthritis (PsA) is a chronic, seronegative spondyloarthropathy characterised by joint inflammation and psoriatic skin changes. Recent data indicate that interleukin-18 (IL-18) and interleukin-20 (IL-20) may be involved in the aetiopathogenesis of PsA.

Aim: To evaluate the potential role of IL-18, IL-20, and matrix metalloproteinases (MMP-1, MMP-3) in the pathogenesis of PsA and their correlations with other markers of inflammation and destruction of joint cartilage, as well as clinical changes.

Material And Methods: The study included 24 patients with PsA and 26 healthy volunteers as a control group. The concentration of IL-18 and IL-20, c-reactive protein (CRP), metalloproteinase-1 and -3 (MMP-1, MMP-3), cartilage oligomeric matrix protein (COMP), aggrecan (PG-AG), and human cartilage glycoprotein (YKL-40) in serum was determined. Clinical severity of the disease according to the BSA, PASI, and DLQI as well as tender and swollen joint count (TJC, SJC) were also evaluated.

Results: The concentration of IL-18 was statistically significantly higher in the serum of patients with PsA than in the control group (62.87 pg/ml vs. 16.73 pg/ml, < 0.0049). Serum IL-20 levels in PsA patients were also higher than in the control group, but without statistical significance ( = 0.2939). The ROC curves showed: AUC = 0.81 for IL-18, AUC = 0.75 for IL-20, AUC = 0.96 for COMP, and AUC = 0.89 for MMP-3.

Conclusions: IL-18 and IL-20 as well as MMP-3 and COMP may be sensitive markers in the diagnosis of PsA.

Citing Articles

Drug- or Vaccine-Induced/Aggravated Psoriatic Arthritis: A Systematic Review.

Yeh Y, Tsai T Dermatol Ther (Heidelb). 2024; 14(1):59-81.

PMID: 38183617 PMC: 10828154. DOI: 10.1007/s13555-023-01082-z.

Anti-Inflammatory Effects of Dietary Polyphenols through Inhibitory Activity against Metalloproteinases.

Suzuki T, Ohishi T, Tanabe H, Miyoshi N, Nakamura Y Molecules. 2023; 28(14).

PMID: 37513300 PMC: 10385587. DOI: 10.3390/molecules28145426.

Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review.

Kimak A, Robak E, Makowska J, Wozniacka A J Clin Med. 2023; 12(11).

PMID: 37298045 PMC: 10253876. DOI: 10.3390/jcm12113850.

Biomarkers in psoriatic arthritis: A meta-analysis and systematic review.

Wirth T, Balandraud N, Boyer L, Lafforgue P, Pham T Front Immunol. 2022; 13:1054539.

PMID: 36532039 PMC: 9749424. DOI: 10.3389/fimmu.2022.1054539.

Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices.

Geneva-Popova M, Popova-Belova S, Popova V, Chompalov K, Batalov A Rheumatol Int. 2022; 42(9):1605-1615.

PMID: 35708757 DOI: 10.1007/s00296-022-05159-4.

References

Ruan G, Xu J, Wang K, Wu J, Zhu Q, Ren J . Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis. Osteoarthritis Cartilage. 2018; 26(8):1063-1069. DOI: 10.1016/j.joca.2018.05.003. View

Gottlieb A, Mease P, Jackson J, Eisen D, Xia H, Asare C . Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat. 2006; 17(5):279-87. DOI: 10.1080/09546630600823369. View

Smeets R, van de Loo F, Arntz O, Bennink M, Joosten L, van den Berg W . Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice. Gene Ther. 2003; 10(12):1004-11. DOI: 10.1038/sj.gt.3301986. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Wei C, Chen W, Wang Y, Chen P, Lee J, Wong T . Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol. 2005; 117(1):65-72. DOI: 10.1016/j.clim.2005.06.012. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

Ahmed S, Attia E, Saad A, Sharara M, Fawzy H, El Nahrery E . Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. J Eur Acad Dermatol Venereol. 2014; 29(4):682-8. DOI: 10.1111/jdv.12653. View

Coates L, Kavanaugh A, Mease P, Soriano E, Acosta-Felquer M, Armstrong A . Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016; 68(5):1060-71. DOI: 10.1002/art.39573. View

Wei C, Hsu Y, Li H, Wang Y, Hsieh M, Chen W . IL-20: biological functions and clinical implications. J Biomed Sci. 2006; 13(5):601-12. DOI: 10.1007/s11373-006-9087-5. View

10.

Olee T, Hashimoto S, Quach J, Lotz M . IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. J Immunol. 1999; 162(2):1096-100. View

11.

Jensen P, Wiell C, Milting K, Poggenborg R, Ostergaard M, Johansen J . Plasma YKL-40: a potential biomarker for psoriatic arthritis?. J Eur Acad Dermatol Venereol. 2012; 27(7):815-9. DOI: 10.1111/j.1468-3083.2012.04570.x. View

12.

Mease P . Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds.... Arthritis Care Res (Hoboken). 2012; 63 Suppl 11:S64-85. DOI: 10.1002/acr.20577. View

13.

Gracie J, Forsey R, Chan W, Gilmour A, Leung B, Greer M . A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999; 104(10):1393-401. PMC: 409841. DOI: 10.1172/JCI7317. View

14.

Chang C, Gottlieb A, Lizzul P . Management of psoriatic arthritis from the view of the dermatologist. Nat Rev Rheumatol. 2011; 7(10):588-98. DOI: 10.1038/nrrheum.2011.125. View

15.

Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E . Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol. 2008; 160(2):284-96. DOI: 10.1111/j.1365-2133.2008.08890.x. View

16.

Ashcroft D, Wan Po A, Williams H, Griffiths C . Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999; 141(2):185-91. DOI: 10.1046/j.1365-2133.1999.02963.x. View

17.

Kragstrup T, Greisen S, Nielsen M, Rhodes C, Stengaard-Pedersen K, Hetland M . The interleukin-20 receptor axis in early rheumatoid arthritis: novel links between disease-associated autoantibodies and radiographic progression. Arthritis Res Ther. 2016; 18:61. PMC: 4788924. DOI: 10.1186/s13075-016-0964-7. View

18.

Przepiera-Bedzak H, Fischer K, Brzosko M . Serum Interleukin-18, Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome. Int J Mol Sci. 2016; 17(8). PMC: 5000653. DOI: 10.3390/ijms17081255. View

19.

Waszczykowska A, Gos R, Waszczykowska E, Dziankowska-Bartkowiak B, Jurowski P . Assessment of skin microcirculation by laser Doppler flowmetry in systemic sclerosis patients. Postepy Dermatol Alergol. 2014; 31(1):6-11. PMC: 3952049. DOI: 10.5114/pdia.2014.40653. View

20.

Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M . Interferon-gamma-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001; 44(2):275-85. DOI: 10.1002/1529-0131(200102)44:2<275::AID-ANR44>3.0.CO;2-B. View